Funds to Support Completion of Clinical Program Through Commercialization of Novel Device Designed to Prevent Amputations in Patients with Chronic Limb-Threatening Ischemia LimFlow SA, a pioneer
/PRNewswire/ Freenome, a privately held biotech company, today announced a Series D funding of $300 million. This brings the company s total financing to.